Your browser is no longer supported. Please, upgrade your browser.
XENE Xenon Pharmaceuticals Inc. monthly Stock Chart
XENE [NASD]
Xenon Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.88 Insider Own1.30% Shs Outstand35.00M Perf Week8.26%
Market Cap396.95M Forward P/E- EPS next Y-1.27 Insider Trans-1.74% Shs Float32.72M Perf Month20.13%
Income-27.00M PEG- EPS next Q-0.39 Inst Own81.30% Short Float2.46% Perf Quarter-4.76%
Sales30.30M P/S13.10 EPS this Y5.20% Inst Trans0.52% Short Ratio7.92 Perf Half Y-13.04%
Book/sh4.98 P/B2.29 EPS next Y-47.70% ROA-13.60% Target Price- Perf Year-0.78%
Cash/sh5.48 P/C2.08 EPS next 5Y- ROE-17.40% 52W Range7.00 - 18.45 Perf YTD-13.04%
Dividend- P/FCF- EPS past 5Y-29.80% ROI-42.80% 52W High-38.21% Beta1.35
Dividend %- Quick Ratio11.50 Sales past 5Y-24.80% Gross Margin- 52W Low62.86% ATR0.71
Employees100 Current Ratio11.50 Sales Q/Q88.60% Oper. Margin- RSI (14)55.40 Volatility6.02% 7.36%
OptionableYes Debt/Eq0.00 EPS Q/Q25.70% Profit Margin-88.90% Rel Volume1.06 Prev Close11.34
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume101.88K Price11.40
Recom1.20 SMA204.76% SMA503.58% SMA200-6.12% Volume107,602 Change0.53%
Oct-02-20Initiated SVB Leerink Outperform $22
Jul-21-20Initiated Needham Buy $22
Jun-01-20Resumed Jefferies Buy $23
Mar-25-20Initiated Wedbush Outperform $23
Jan-08-20Initiated William Blair Outperform
Sep-20-19Initiated Guggenheim Buy $25
Aug-08-18Reiterated Stifel Buy $9 → $15
Mar-13-17Initiated Jefferies Buy $13
Oct-21-16Initiated Stifel Buy $18
Sep-26-16Initiated Guggenheim Buy $20
Apr-14-16Reiterated Jefferies Buy $10 → $13
Oct-30-15Resumed Jefferies Buy
Dec-02-14Initiated Canaccord Genuity Buy $15
Nov-13-20 09:00AM  
Nov-09-20 02:15PM  
Nov-07-20 12:31AM  
Nov-06-20 01:35PM  
Nov-05-20 06:45PM  
04:01PM  
02:45PM  
Nov-02-20 05:26PM  
Oct-08-20 08:02AM  
08:00AM  
Sep-28-20 08:02PM  
Sep-22-20 03:41PM  
Aug-17-20 08:30AM  
Aug-06-20 08:20PM  
04:01PM  
Aug-04-20 04:01PM  
Jul-30-20 04:01PM  
Jul-12-20 01:31PM  
Jun-17-20 04:04PM  
Jun-08-20 02:06AM  
Jun-01-20 04:20PM  
11:31AM  
May-25-20 08:28AM  
May-22-20 10:23AM  
04:30AM  
May-21-20 05:15PM  
04:01PM  
02:30PM  
May-14-20 04:01PM  
Mar-31-20 08:30AM  
Mar-28-20 12:12AM  
Mar-26-20 04:01PM  
Mar-23-20 09:06AM  
Mar-09-20 04:01PM  
02:30PM  
Mar-02-20 04:01PM  
Feb-14-20 11:11AM  
Feb-06-20 11:53AM  
Feb-04-20 11:44AM  
08:13AM  
Feb-03-20 11:11AM  
Jan-27-20 04:01PM  
Jan-24-20 10:26AM  
Jan-23-20 12:00PM  
07:24AM  
Jan-22-20 08:49PM  
04:01PM  
Jan-13-20 08:30AM  
Jan-10-20 08:08AM  
Dec-11-19 11:23AM  
Dec-07-19 08:45AM  
Dec-06-19 08:45AM  
Dec-03-19 05:23PM  
07:59AM  
Dec-02-19 07:45AM  
07:30AM  
Nov-21-19 09:44AM  
Nov-15-19 08:45AM  
Nov-11-19 09:45AM  
Nov-05-19 04:01PM  
Oct-29-19 04:30PM  
Oct-25-19 02:20PM  
Oct-16-19 08:30AM  
Oct-01-19 07:21AM  
Sep-25-19 04:05PM  
11:49AM  
Sep-24-19 09:36AM  
Sep-17-19 04:05PM  
Sep-09-19 04:01PM  
Sep-05-19 11:22AM  
Aug-14-19 12:51PM  
Aug-06-19 09:33PM  
Jul-31-19 04:01PM  
Jul-09-19 11:11AM  
Jun-14-19 06:55PM  
Jun-05-19 08:10AM  
Jun-03-19 05:58PM  
May-29-19 04:19PM  
May-21-19 03:18PM  
May-15-19 12:31PM  
May-07-19 05:19PM  
04:01PM  
Apr-30-19 04:01PM  
Apr-24-19 04:01PM  
Apr-04-19 09:00AM  
Mar-13-19 02:02AM  
Mar-06-19 04:01PM  
02:30PM  
07:39AM  
Feb-27-19 04:01PM  
Feb-26-19 07:30AM  
Jan-28-19 08:00AM  
Jan-18-19 12:24PM  
Jan-06-19 09:00PM  
Dec-26-18 02:14PM  
Dec-19-18 01:54AM  
Dec-03-18 07:30AM  
Nov-30-18 09:00AM  
Nov-19-18 01:51PM  
Nov-16-18 11:56AM  
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy. The company's product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in Phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase I clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop first-in-class treatments for epilepsy. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TARNOW MICHAEL MDirectorOct 28Option Exercise3.7610,28838,68380,001Oct 29 04:27 PM
PATOU GARYDirectorOct 28Option Exercise3.762,0577,73423,573Oct 29 04:20 PM
TARNOW MICHAEL MDirectorJun 09Option Exercise3.525,14418,10769,713Jun 10 05:17 PM
ROBIN SHERRINGTONEVP, Strategy & InnovationJun 01Option Exercise3.568,23029,29918,426Jun 02 05:40 PM
PIMSTONE SIMON N.CEOJun 01Sale14.433,00043,290255,186Jun 02 04:50 PM
HOLLER FRANK ADirectorMay 29Option Exercise3.563,08610,986122,041Jun 02 04:54 PM
PIMSTONE SIMON N.CEOMay 29Sale13.995,00069,950258,186Jun 02 04:50 PM
PIMSTONE SIMON N.CEOMay 26Option Exercise3.566,17221,972264,294May 28 05:02 PM
AZAB MOHAMMADDirectorDec 16Option Exercise3.563,08610,98660,647Dec 17 05:04 PM
PATOU GARYDirectorDec 04Option Exercise3.562,0577,32321,516Dec 06 05:12 PM